AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR12 Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis

Document -

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR12 Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis

New data demonstrated high SVR12 rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment
  • License: All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf

Contacts

General Press Enquiries

Press contact 01628 925200

Joanna Jones

Press contact Head of Brand Communications and Patient Relations 07795 590 344

Cheryl Pitcher

Press contact Senior Corporate Communications Manager Internal and Corporate Communications 07500 786 466

Natalie Bennett

Press contact Senior Communications and Patient Relations Manager Immunology - Gastroenterology & Rheumatology 07818 428 074

Sarah Beck

Press contact Senior Brand Communications and Patient Relations Manager, Dermatology Dermatology 07818 428 111

Related content

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR12 Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis

New data demonstrated high SVR12 rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment